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A 5‑lipoxygenase-speciﬁc sequence motif impedes enzyme activity and
confers dependence on a partner protein
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Leukotrienes (LT) are lipid mediators of the inﬂammatory response that play key roles in diseases such as asthma
and atherosclerosis. The precursor leukotriene A4 (LTA4) is synthesized from arachidonic acid (AA) by 5‑lipoxygenase (5-LOX), a membrane-associated enzyme, with the help of 5‑lipoxygenase-activating protein (FLAP),
a nuclear transmembrane protein. In lipoxygenases the main chain carboxylate of the C-terminus is a ligand for
the non-heme iron and thus part of the catalytic center. We investigated the role of a lysine-rich sequence
(KKK653–655) 20 amino acids upstream of the C-terminus unique to 5-LOX that might displace the main-chain
carboxylate in the iron coordination sphere. A 5-LOX mutant in which KKK653–655 is replaced by ENL was
transfected into HEK293 cells in the absence and presence of FLAP. This mutant gave ~20-fold higher 5-LOX
product levels in stimulated HEK cells relative to the wild-type 5-LOX. Co-expression of the enzymes with FLAP
led to an equalization of 5-LOX products detected, with wild-type 5-LOX product levels increased and those from
the mutant enzyme decreased. These data suggest that the KKK motif limits 5-LOX activity and that this attenuated activity must be compensated by the presence of FLAP as a partner protein for eﬀective LT biosynthesis.

1. Introduction
The biosynthesis of leukotrienes (LT), lipid mediators of the inﬂammatory response, is initiated by 5‑lipoxygenase (5-LOX) [1,2]. 5LOX translocates to the nuclear membrane upon intracellular Ca2+
mobilization [3,4], along with phospholipase A2 (PLA2). PLA2 cleaves
arachidonic acid (AA) from phospholipids that form the nuclear bilayer
so that it is then available for 5-LOX to be converted to LTA4. Additionally, 5-LOX requires a helper protein, termed 5‑lipoxygenase-activating protein (FLAP), a nuclear membrane-embedded AA-binding
protein that facilitates substrate access and promotes completion of the
two-step transformation of AA to LTA4 [5–8]. This transformation
proceeds via (i) hydrogen abstraction at C7 and the oxygenation of AA
at C5 and (ii) hydrogen abstraction from the 5‑hydroperoxyeicosatetraenoic acid (5-HPETE) intermediate at C10 to generate
LTA4 [9,10] (Fig. S1). 5-LOX and FLAP co-localize at the nuclear
membrane and are suggested to interact in order for FLAP to eﬃciently
transfer AA as substrate to 5-LOX [11–14].
5-LOX is a short-lived enzyme [15–18], as is ﬁtting for an enzyme
that initiates the synthesis of inﬂammatory mediators that activate G-

⁎

protein coupled receptors at nanomolar concentrations [19–21]. The
eﬀects of overproduction of 5-LOX-generated lipid mediators are exhibited in pathologies such as asthma and atherosclerosis. Auto-inactivation has been proposed to play an important regulatory role in
temporal control of 5-LOX activity [22,23].
In the course of constructing a 5-LOX mutant amenable to structural
studies we found that replacement of KKK653–655 with its counterpart
from a stable 5-LOX homologue (i.e. ENL) improved in vitro stability.
This variant was also trimmed of its membrane-insertion loops and two
Cys-residues near the active site and was given the moniker Stable-5LOX [24]. The structural basis for KKK653–655-invoked instability was
easy to rationalize: the presence of K655 (where LOX homologues have
a highly conserved Leu) positions a charged amino acid for repulsion
with the invariant R651 (Fig. 1). The carboxy termini of LOXs insert
into the catalytic domains so that the terminal, backbone carboxyl
serves as a ligand for the catalytic iron. The 5-LOX KKK motif lies in the
turn that allows the main chain carboxyl to circle back and ligate the
catalytic iron.
We replaced the KKK653–655 sequence with ENL, the sequence present in a typical lipoxygenase with a robust catalytic activity [25,26],
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Fig. 1. Structural perspective of the KKK653–655
motif. A. Two 5-LOX cartoon diagrams related
by a 180° rotation. The “Tail” and “Body” antibody epitopes are highlighted in green and blue,
respectively. The mutant residues (ENL) that
replace KKK653–655 are shown in stick rendering
in magenta. B. Sequence comparison of human
5-LOX and other LOXs highlighting the conserved Arg651 (blue) and the unique 5-LOX
Lys655 where there is a highly conserved Leu
(magenta). C. The KKK653–655 sequence is located at the turn between the C-terminal helix
and carboxy-terminus, which is a ligand for the
catalytic non-heme iron. The “Tail” epitope
(green), and the conserved Arg and Leu (blue
and magenta) are depicted.

into a WT-5-LOX expression construct (yielding the so-called Triple-KMutant-5-LOX, TKM-5-LOX) to investigate the role of this KKK motif.
We observed that HEK cells expressing TKM-5-LOX display a ~20-fold
increase of 5-LOX product formation relative to the wild-type enzyme.
In parallel experiments with Ca2+-ionophore-stimulated cells we see an
accelerated loss of the TKM-5-LOX, being subject to turnover-based
inactivation like WT-5-LOX [16]. However, when co-expressed with
FLAP, 5-LOX products detected in HEK cells for the mutant and wildtype enzyme are equivalent. Our data suggest that the KKK motif is a
governor of 5-LOX enzyme activity and the helper protein FLAP is required to suﬃciently relieve its auto-suppression for eﬀective LT
synthesis. Moreover, substrate sequestering and/or handoﬀ by FLAP
may limit the rate of LTA4 synthesis by the hyperactive TKM-mutant.

peptide and migrates at the same molecular weight as the puriﬁed
enzyme.
The TKM-5-LOX is also more resistant to chymotrypsin in crude cell
lysates. Intact HEK cells expressing WT- or TKM-5-LOX (but not FLAP)
were ﬁrst treated with (or without) Ca2+-ionophore A23187. Cell lysates were prepared and incubated with and without chymotrypsin. The
proteins (fragments) of the incubations were analyzed by Western blot
using the Tail antibody. It is important to note that the cleavage bands
observed in samples incubated without chymotrypsin demonstrate the
enzyme's susceptibility to endogenous cellular proteases upon cell lysis,
as the experiments were free of protease inhibitors. Fragments detected
for WT-5-LOX are more pronounced than in the lysates of TKM-5-LOXexpressing cells (Fig. 3).

2. Results

2.2. Co-localization of 5-LOX and FLAP at the nuclear membrane appears
unaﬀected by substitution of the KKK motif

2.1. Substitution of the KKK653–655 motif stabilizes 5-LOX against
proteolysis

Immunoﬂuorescence microscopy studies indicate that like the wildtype enzyme [11,27], the TKM-5-LOX variant translocates to the nuclear membrane upon stimulation with Ca2+-ionophore, both in the
absence and presence of FLAP (Fig. 4). Detection by both “Body” and
“Tail” antibody demonstrated that TKM-5-LOX colocalizes with FLAP,
as seen for the wild-type enzyme (Fig. S2). Additionally, the TKM-5LOX displays the same cytoplasmic localization as WT-5-LOX when
unstimulated. Representative immunoﬂuorescence images are presented in Fig. 4.

In order to establish that the mutation of KKK to ENL did not inadvertently disrupt the 5-LOX protein fold, we subjected both the
puriﬁed wild-type and mutant enzymes to limited proteolysis by chymotrypsin. The enzymes were incubated with the protease in the absence and presence of Ca2+. TKM-5-LOX exhibited a higher resistance
to cleavage by chymotrypsin than WT-5-LOX when the proteins were
assessed with two distinct antibodies: one speciﬁc for the C-terminal
twelve amino acids (“Tail”) and the other for the amino acids 130–149
(“Body”) (Fig. 2, antibody epitopes highlighted in Fig. 1). Essentially,
little to none of the full-length enzyme was detected by either antibody
when puriﬁed WT-5-LOX was incubated with chymotrypsin, implying
its completed proteolysis. In contrast, in these same conditions the
TKM-5-LOX remained largely intact. The major band detected for the
TKM-5-LOX after exposure to protease is likely to be full-length enzyme
given that it is recognized by an antibody raised to the C-terminal

2.3. HEK cells expressing TKM-5-LOX yield elevated levels of 5-LOX
products
TKM-5-LOX was expressed in HEK293 cells at levels comparable to
the WT-5-LOX, as judged by mRNA and protein levels, detected by
qPCR (Fig. S3) and Western blotting, respectively (vida infra, Section
2.5). 5-LOX-expressing HEK cells devoid of FLAP were incubated with
544
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Fig. 2. In vitro chymotrypsin cleavage analysis. WT5-LOX and TKM-5-LOX cleavage patterns with
“Body”
(left)
or
“Tail”
(right)
antibody
development, ± Ca2+ and/or chymotrypsin. WT-5LOX displays susceptibility to chymotrypsin cleavage, while TKM-5-LOX is strikingly more resistant.
The lane containing the molecular weight markers is
labelled “mwm.”

[27], co-expression of FLAP in HEK cells together with 5-LOX caused a
~4 fold increase in product formation by WT-5-LOX [27] (Fig. 5). In
contrast, co-expression of FLAP reduced product formation of TKM-5LOX down to the levels of WT-5-LOX (TKM 53 ng 5-HETE, 28 ng LTs;
WT 43 ng 5-HETE; 23 ng LTs). Thus, the presence of FLAP elevates the
activity of WT-5-LOX but attenuates the increased activity of the TKM
mutant in these assay conditions.
In addition, we compared the kinetics of product formation in HEK
cells co-expressing FLAP and WT- or TKM-5-LOX. Ultra Performance
Liquid Chromatography (UPLC)-MS/MS analysis was performed with
cells stimulated with ionophore and AA (added at t0) and 5-LOX products sampled at 30, 60, 120, 180, 360 and 600 s. Again, the presence
of FLAP led to similar levels of products generated by both cells types,
with no signiﬁcant diﬀerences detected at early (< 300 s) or late
(600 s) time points when total 5-LOX products are summed (Fig. 6).
Both cell lines reached the plateau for 5-LOX products at the same time
points (180 s), indicating no diﬀerences in their ability to metabolize
AA. When 5-HETE and LTB4-breakdown products are plotted individually, the kinetics of 5-HETE production in the two cell lines agree
more than those of LT production, with the latter at higher levels in the
WT-5-LOX-expressing cells. However, again at 10 min the diﬀerence
between the LT levels in the two cell types does not appear signiﬁcant
(Figs. 5, 6). These data support the conclusion that the presence of FLAP
reduces TKM-5-LOX product formation to WT-5-LOX levels.

Fig. 3. Chymotrypsin cleavage patterns of WT-5-LOX or TKM-5-LOX in lysates
of HEK cells. Cells were ﬁrst treated with or without Ca2+-ionophore (A21387),
lysed, incubated with or without chymotrypsin, and then developed with the
“Tail” primary antibody. Lanes labelled “mwm” and “UT” correspond to the
molecular weight markers and lysates of untransfected cells, respectively. Note
the intensity of the lower molecular weight band generated by chymotrypsin for
the WT-5-LOX relative to the full-length protein band.

2.5. The substitution of KKK promotes loss of enzyme in conditions in which
substrate is available

or without Ca2+-ionophore and 3 μM AA was added at 5 min. At this
concentration of AA the bulk of the substrate is expected to partition
into the bilayer and is accessible to 5-LOX when translocated to the
membrane. Both the ﬁnal LTA4 hydrolysis products (combined as LT)
and the intermediate were quantitated by high-pressure liquid chromatography (HPLC) analyses. The 5-HPETE intermediate is detected as
the reduced alcohol 5‑hydroxyeicosatetraenoic acid (5-HETE). As expected, 5-LOX product formation was only detected in cells stimulated
with Ca2+-ionophore. In the absence of FLAP, TKM-5-LOX-expressing
cells yielded strikingly higher overall product levels (~190 ng 5-HETE,
~65 ng LT) compared to WT-5-LOX cells (~9 ng 5-HETE, ~3 ng LT,
Fig. 5). However, the proportion of LTA4 hydrolysis products relative to
5-HETE is roughly the same (~33%). This ~20-fold higher product
formation cannot be explained by elevated protein expression levels
and suggests that TKM-5-LOX has signiﬁcantly augmented, or prolonged, enzyme activity over WT-5-LOX.

We next monitored 5-LOX protein levels in the HEK cells in order to
investigate whether the increased product levels of the TKM-5-LOX
might be a consequence of increased enzyme longevity (Fig. 7). Using a
method adapted from that described by Dai et al. [28], 5-LOX protein
levels (relative to the house-keeping protein GAPDH) in the presence of
the protein synthesis inhibitor cycloheximide were monitored in HEK
cells for 4 h by Western blot. These experiments were performed in the
presence or absence of Ca2+-ionophore: in the presence of Ca2+-ionophore 5-LOX becomes activated and translocates to the nuclear membrane to access AA. It is important to point out that exogenous AA was
not added to the incubation with cycloheximide, and that only endogenous AA (liberated by PLA2 upon Ca2+ ionophore stimulation) is
available.
In the absence of Ca2+-ionophore, the levels of WT- and TKM-5-LOX
remained roughly stable up to 4 h, regardless of the presence of FLAP.
In these conditions, the WT-5-LOX appears to be expressed at slightly
elevated levels versus TKM-5-LOX (Fig. 7) (5-LOX/GAPDH ratios at
0.6 ± 0.20 for WT-5-LOX and 0.3 ± 0.15 for TKM-5-LOX). Upon
Ca2+-ionophore stimulation of cells devoid of FLAP, the levels of the

2.4. Co-expression of FLAP reduces product formation of TKM-5-LOX to
the levels of WT-5-LOX
In parallel experiments and in agreement with previous ﬁndings
545
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A

-FLAP
Unstimulated

B
Stimulated

+FLAP
Stimulated

Fig. 4. Cellular localization of 5-LOX variants in HEK 293 cells. A. WT-5-LOX- and TKM-5-LOX-expressing HEK cells in the absence (unstimulated) and presence
(stimulated) of Ca2+-ionophore A23187, detected with “Body” or “Tail” primary antibodies. The nucleus is indicated by DAPI (blue) and 5-LOX by AlexaFluor-488
(green). In the absence of Ca2+-ionophore the enzymes are dispersed in the nucleus and cytoplasm. Once stimulated clear “rings” surround the nuclear DNA staining.
B. When expressed with FLAP, both WT-5-LOX and TKM-5-LOX co-localize with FLAP in the presence of Ca2+-ionophore, as detected with either “Body” or “Tail”
primary antibodies. FLAP is indicated with AlexaFluor-647 (red). Combined TRITC and Cy5 channels demonstrated co-localization of 5-LOX and FLAP at the nuclear
membrane as conﬁrmed by ImageJ co-localization analysis. (Supplemental Fig. 2).

Fig. 5. 5-LOX activity in HEK 293 cells. A. The TKM-5-LOX displays a robust activity in intact HEK cells. HEK cells expressing WT-5-LOX or TKM-5-LOX ± FLAP
(with Ca2+-ionophore stimulation) were incubated with 3 μM AA. Leukotrienes (gray) and 5-HETE (black) were determined by HPLC analysis. 5-LOX products were
not detected in the absence of Ca2+-ionophore. TKM-5-LOX exhibits a signiﬁcant increase in product formation relative to WT-5-LOX. B. Levels of LTA4 hydrolysis
products detected relative to the 5-HETE intermediate. WT-5-LOX and TKM-5-LOX without FLAP have equivalent LT/5-HETE ratios but when co-expressed with
FLAP the mutant displays an increase in the proportion of LTA4 hydrolysis products. C. The striking increase in activity of the TKM-5-LOX is not observed in cell
homogenates. Product formation of the WT and mutant enzyme are comparable when assayed in cell homogenates. ****P < 0.0001, **P < 0.01, *P < 0.1
Statistical analysis performed with Graphpad Prism version 7.

the enhanced in vitro stablity. Moreover, TKM-5-LOX levels decline in
conditions in which it can produce 5-HETE or LTA4.
Previous work indicated that 5-LOX products are only detected in
the 5-LOX expressing HEK293 cells when exogenous arachidonic acid is
added [27]. However, we conﬁrmed the presence and availability of
endogenous AA by increasing the sample size (5 × 106 vs. 1 × 106
cells). The UV spectrum displayed in Fig. 8 is consistent with the presence of LTA4 hydrolysis products in extracts of HEK293 cells co-

TKM-5-LOX declined within 90 min, while those for the WT-5-LOX
much less so. The loss of TKM-5-LOX is consistent with its enhanced
enzyme activity and turnover-based inactivation as previously described for 5-LOX [16]. In contrast, when co-expressed with FLAP,
where 5-LOX product levels of WT- and TKM-5-LOX are comparable,
the levels of TKM-5-LOX remain stable. These data suggest that the
increase in product yields from TKM-5-LOX (without its partner FLAP)
is not a consequence of a prologoned half-life for TKM-5-LOX, despite
546
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Fig. 6. Time-dependent 5-LOX product analysis. HEK-WT-5-LOX + FLAP and HEK-TKM-5-LOX + FLAP were stimulated with 2.5 μM A23187 plus 3 μM AA at 37 °C
and 5-LOX products were quantitated at the indicated time points. Formed lipid mediators were isolated by solid phase extraction and analyzed by UPLC-MS-MS and
are shown as ng/1 × 106 cells. (A) Total 5-LOX products (B) 5-HETE, (C) LTA4 breakdown products. Results were analyzed in n = 3 independent experiments.

and participates in a conserved salt-link with Asp473 and a π-cation
interaction with Phe469 [24]. Thus, a Lys at 655 in WT-5-LOX may
disrupt these interactions and impact the positioning of the C-terminal
Ile673 carboxyl in the Fe2+ coordination sphere. The structure of a
bacterial LOX that harbors a positively charged amino acid at the position corresponding to 5-LOX Lys655 conﬁrmed this prediction: the
invariant Arg (Arg651) that participates in a conserved salt link has
been displaced in this enzyme [29].
The mutation of the KKK to ENL was performed to engineer a 5-LOX
variant for crystallographic studies, and it was observed that the mutation increased the melting temperature of the mutant protein [24].
This led us to suggest that the KKK motif might contribute to an

expressing FLAP and TKM-5-LOX and stimulated with Ca2+-ionophore.
3. Discussion
3.1. Structural impact of the triple-lysine motif
The KKK653–655 sequence is located 20-amino acids up stream of the
C-terminal Ile673, which ligates the active site iron of 5-LOX via its
main chain carboxyl. This unique sequence motif appears to conﬂict
with salt-link and π-cation interactions observed in other LOX structures. K655 of the KKK motif in other LOXs is typically a conserved Leu.
A highly conserved Arg651 lies one turn away on the C-terminal helix

Fig. 7. In the absence of de novo protein synthesis WT 5-LOX levels remain constant in HEK 293 cells. A. Western blots of WT- and TKM-5-LOX. WT-5-LOX and TKM5-LOX ± FLAP – expressing HEK cells were incubated with cycloheximide over a four-hour period. Western blots for both 5-LOX and the housekeeping enzyme
GAPDH (lower panel) at time points 0, 60, 90, 120, 150, 180, 210, and 240 min in the absence (top) and presence (bottom) of Ca2+-ionophore A21387 were
developed with “Tail” antibody. Both mutant and WT-5-LOX levels remain stable in the absence of Ca2+-ionophore. Post-stimulation TKM-5-LOX levels decline when
FLAP is absent. Representative Westerns are depicted for each of the experiments. B. Triplicate/duplicate plots (black, gray and white circles) of the ratio of 5-LOX to
GAPDH levels, as determined from band densities. Although diﬀerences in expression levels are observed between duplicate and triplicate experiments, the trends are
equivalent. Cycloheximide is not stable for the entire time period and was replenished at 120 min. Quantiﬁcation of 5-LOX variants was measured relative to GAPDH
density with ImageJ. Only TKM-5-LOX, when expressed in the absence of FLAP, displays a signiﬁcant decline in enzyme detected in the ﬁrst 90 min after stimulation.
547
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10 min of incubation.
While the presence of FLAP increases the LT biosynthetic capacity of
the WT-5-LOX-expressing cells, the TKM-5-LOX-expressing cells display
a signiﬁcantly reduced LT biosynthetic eﬃciency when FLAP is present.
Interestingly, the pronounced increase in product formation by TKM-5LOX is only apparent in incubations with intact cells, as assays of cell
homogenates have similar product yields (Fig. 5c). Similarly, the impact of FLAP on 5-LOX product formation is only observed in intact
cells [7]. The presence of an intact nuclear membrane may be essential
for both processes.
It is tempting to speculate on how the presence of FLAP equalizes
the product levels for WT- and TKM-5-LOX. Our data may suggest that
the transfer of AA from FLAP to 5-LOX is the rate-limiting step of the
transformation of AA to LTA4. For the WT-5-LOX, FLAP increases its
access to substrate. However, the more robust activity of TKM is obscured when it must access FLAP-sequestered AA. FLAP serves as a
gatekeeper. An alternative model is that a FLAP-induced conformational change in 5-LOX abrogates the eﬀect of the KKK to ENL mutation
by constraining the conformations it can sample in catalysis. For example, any eﬀect of the mutation on the Fe2+ coordination sphere may
be negated once 5-LOX and FLAP interact. Either model is consistent
with the suggestion that a speciﬁc FLAP:5-LOX interaction allows FLAP
to rescue 5-LOX mutants with impaired enzyme and membrane-binding
activities [11].
In intact cells FLAP is able to compensate for the lower activity of
the WT-5-LOX to some extent. Thus, we suggest that the KKK motif
confers the requirement for FLAP for rapid initiation of LT biosynthesis.
This regulatory mechanism is reminiscent of the cyclin/cyclin-dependent kinase scenario, where an enzyme (the kinase) requires interaction
with a binding partner to promote catalytic competence [30]. Overproduction of LTs as pro-inﬂammatory mediators is detrimental to the
organism, thus the tempered activity of 5-LOX that relies on alleviation
by a protein partner limits this possibility. WT-5-LOX alone is particularly ineﬃcient at producing lipid mediators but stimulated by FLAP it
still does not reach the levels produced by the TKM-5-LOX expressed
without FLAP. The fact that the presence of FLAP obviates the marked
increase in 5-LOX product formation by TKM-5-LOX suggests that the
KKK motif is not required for interaction with FLAP.

Fig. 8. TKM-5-LOX FLAP expressing cells produce LT from endogenous AA.
(Left) The UV-spectrum of the gray fraction is consistent with LTA4 hydrolysis
products. (Right) Overall proportions of extracted oxylipins from TKM-5-LOX
FLAP cells stimulated with Ca2+-ionophore A21387.

atypically short half-life compared to other LOXs [22]. TKM-5-LOX is
indeed less susceptible to protease than the wild-type as the puriﬁed
enzyme, or in crude cell lysates. However, we observed that the levels
of both WT-5-LOX and TKM-5-LOX remain stable in unstimulated HEK
cells, despite the pronounced instability of the former under cell-free
conditions. In experiments to determine if the increased stability of
TKM-5-LOX is reﬂected as a longer half-life in a cellular context we
monitored enzyme levels in cells in which protein synthesis was inhibited. In the absence of stimulation the band densities for the WT- and
TKM-5-LOX remain stable in the presence or absence of FLAP over 4 h.
Thus, the protease sensitivity of the WT enzyme observed in cell-free
conditions does not appear to aﬀect protein levels in a cellular context,
and the increased activity of TKM-5-LOX in intact HEK cells is not
simply due to higher levels of enzyme expression or longer half-life.
In contrast, inclusion of Ca2+-ionophore that enables the enzyme to
access liberated endogenous AA, leads to a loss of the TKM-5-LOX
protein levels in cells devoid of FLAP in the ﬁrst 90 min of incubation.
In contrast, in cells expressing WT-5-LOX ± FLAP or TKM-5-LOX with
FLAP, LOX levels remained stable. Thus, only the hyperactive TKM
mutant levels decay, suggesting that the loss of TKM-5-LOX is a consequence of catalysis, as is consistent with the increased products
generated by TKM-5-LOX with exogenously added AA. Notably, in the
absence of exogenous AA there is suﬃcient endogenous AA released by
the action of PLA2 to observe enzyme activity, and its consequent
decay. In those cells that generate lower levels of product, 5-LOX enzyme levels remain stable.

3.3. Turnover based inactivation
By monitoring 5-LOX protein levels in the presence of an inhibitor of
protein biosynthesis, we observed a turnover-dependent loss of TKM-5LOX. In the absence of Ca2+-ionophore, both WT- and TKM-5-LOX
exhibited stable protein levels. However, in the presence of Ca2+-ionophore there is a decline in the level of TKM-5-LOX detected in intact
cells after 90 min (Fig. 7). The cycloheximide analysis was performed
without addition of exogenous AA. However, we can detect the products of TKM-5-LOX activity in Ca2+-ionophore-stimulated HEK cells
without addition of exogenous AA (Fig. 8) and conﬁrm that endogenous
AA is released from the phospholipids upon stimulation. The presence
of endogenous phospholipid-esteriﬁed AA that might provide a source
of substrate is supported by data from other groups. Dawaliby et al.
established that HEK293 cell membranes contain C20 containing
phospholipids [31]. More speciﬁcally, Zhu et al. [32] report the presence of 20:4n-6 fatty acids in the cell membrane phospholipids of
HEK293 cells. Additionally, HEK cells transfected to express 12-LOX
generate product without the addition of exogenous AA when cultured
in DMEM [27]. Therefore, the elevated product levels detected in HEK
cells expressing TKM-5-LOX in the presence of exogenous AA and the
disappearance of TKM-5-LOX, once stimulated with Ca2+-ionophore to
promote release of endogenous PL-esteriﬁed AA, are consistent with
turnover-based inactivation.

3.2. The presence of FLAP equalizes the capacities to generate 5-LOX
products
We have demonstrated that the KKK653–655 sequence is a unique 5LOX structural feature that acts as an intrinsic regulator of 5-LOX to
control the ﬂow of LT biosynthesis. In the absence of FLAP, we observed
a striking diﬀerence in the activities of the WT- and TKM-5-LOX. The
KKK motif severely constrains a robust LOX activity as observed by the
~20-fold increase in product formation when the KKK sequence is
substituted by ENL (Fig. 5), and this 20-fold increase cannot be explained by diﬀerences in enzyme expression levels or enzyme half-life.
However, this increase in activity is not apparent when TKM-5-LOX is
co-expressed with FLAP (Figs. 5, 6). In these conditions, 5-LOX product
levels of WT- and TKM-5-LOX are roughly equivalent. While diﬀerences
in total LTA4 hydrolysis products were observed at intermediate time
points in the cell incubations, this diﬀerence is not signiﬁcant after
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After clariﬁcation of the lysate by centrifugation at 36,000 ×g, the
supernatant was applied to a Co2+-aﬃnity column. The column was
washed with 100 mM Tris, 500 mM NaCl, 20 mM imidazole. The immobilized enzyme was eluted with 100 mM Tris, 500 mM NaCl,
200 mM imidazole. After concentration of the eluent, protein concentration was determined with a Nanodrop spectrophotometer.
Protein purity was conﬁrmed by SDS-PAGE. Puriﬁed protein was frozen
dropwise and stored in liquid N2.

3.4. Intrinsic regulators
The KKK motif might be an integral deactivation sequence that acts
as a regulator of LT biosynthesis. Internal enzyme fail-safe mechanisms
are one of many regulatory mechanisms that keep the intricate web of
biosynthetic pathways in check. An intriguing auto-inactivation mechanism of another LT biosynthetic enzyme has been described for
LTA4 hydrolase. In this enzyme, the presence of Tyr378 makes it susceptible to covalent modiﬁcation by its reactive substrate. Substitution
of Tyr378 with Gln or Ala leads to a variant that is less susceptible to
covalent modiﬁcation, and consequently inactivation, by the substrate
[33–35]. Thus, both 5-LOX and LTA4 hydrolase display auto-suppression of catalytic activity, but through entirely diﬀerent mechanisms.
Other amino acids in 5-LOX have been demonstrated to play signiﬁcant roles in tempering a robust rate of product formation. Rakonjac
et al. examined the signiﬁcance of a salt-link between residues Arg101
and Asp166 of the regulatory and catalytic domains, respectively.
Disruption of this interaction leads to an increase in enzyme activity
[36].
Our studies do not reveal exactly how the presence of the KKK motif
modulates 5-LOX activity. Computational methods, as summarized by
O'Rourke et al., can be combined with high-resolution X-ray data to
reveal possible internal protein communication networks [37]. However, the resolution of the crystal structure of Stable-5-LOX makes this
approach inaccessible at this point. In any case, it is apparent that the
KKK motif signiﬁcantly contributes to tight regulation of 5-LOX activity
as the initiator of LT biosynthesis. This motif, which initially we studied
as a possible mechanism to limit protein half-life, appears to be part of a
more intricate, ﬁnely-tuned control mechanism to regulate LT biosynthesis in conjunction with FLAP.

4.4. Expression of 5-LOX and FLAP in HEK293 cells
HEK293 cells were transfected with WT-5-LOX, TKM-5-LOX, and
FLAP using the pcDNA3.1 vector for stable protein expression as described by Gerstmeier et al. [27]. Cells were cultured at 37 °C, 5% CO2
in Dubelco's Modiﬁed Eagle Medium (DMEM) with 10% fetal bovine
serum (FBS, Atlanta Biologicals), in the presence of selection antibiotic
(G418, 5-LOX; and hygromycin, FLAP (both from Sigma)). Successful
protein expression was conﬁrmed by Western blotting.
4.5. Proteolytic cleavage
4.5.1. Puriﬁed enzyme
Puriﬁed WT- and TKM-5-LOX were diluted to 9.8 μM in 100 mM
Tris, 100 mM NaCl. The puriﬁed protein solutions were incubated with
or without 2.5 μM CaCl2 for 5 min. The solutions were then incubated
with or without 5 μM chymotrypsin (2:1 protein to protease ratio) for
1 min on ice. Samples were run on an SDS-PAGE gel and transferred to a
PVDF membrane with a Bio-Rad Trans-Blot system for Western development. The primary antibodies were rabbit anti-5-LOX “Body” (amino
acids 130–149) and rabbit anti-5-LOX “Tail” (12 amino acids from the
C-terminus). The secondary antibody utilized was goat anti-rabbit
AlexFlour647. Western blots were imaged with a Typhoon 9410 imager
using channel 670 30 BP.

4. Materials and methods
4.1. Materials

4.5.2. Cell lysates
HEK293 cells expressing WT- or TKM-5-LOX were collected and
resuspended at 1 × 106 cells/ml in phosphate-buﬀered saline (PBS)
plus 0.1% glucose. Cells were incubated with or without 2.5 μM Ca2+ionophore A23187 for 5 min in a 37 °C water bath. The cells were spun
down and resuspended in lysis buﬀer (50 mM Tris pH 8.0, 150 mM
NaCl, 1 mM EDTA, 2% Triton-×100) before being incubated with
100 nM chymotrypsin for 1 min on ice. Sample protein concentrations
were determined with a BCA protein assay kit (Pierce). Equivalent
amounts of protein were loaded onto 10% SDS-PAGE gels. After blotting onto PVDF membranes. The resulting Western blots were developed as described above.

The “Tail” antibody was generated by Genscript (Piscataway) to a
peptide with the C-terminal 12 amino acids of 5-LOX: CSPDRIPNSVAI.
Speciﬁcity was conﬁrmed by its ability to detect full-length bacterially
expressed Stable-5-LOX, but not a truncated version of the construct. 5LOX “Body” was purchased from Abcam and is raised to the sequence
QHRRKELETRQKQYRWMEWN (amino acid 130–149). FLAP antibody
was purchased from Abcam (Cambridge) and secondary antibodies
were obtained from Life Technologies (Carlsbad, CA).
4.2. 5-LOX puriﬁcation
His-tagged WT-5-LOX and TKM-5-LOX were expressed in Rosetta
cells with a pET14B vector. Bacteria were cultured at 37 °C and 220 rpm
for 4 h and then at 20 °C for an additional 27 h. Cells expressing WT-5LOX were lysed by sonication and the lysate was clariﬁed by centrifugation at 36,000 ×g for 30 min. To the supernatant was added
ammonium sulfate to 50% saturation. The precipitant was pelleted and
resuspended in 100 mM Tris, 100 mM NaCl, 5 mM Imidazole, 2 mM tris
(2‑carboxyethyl)phosphine (TCEP), 10 μM FeSO4. The resuspended
precipitant was applied to a Co2+-aﬃnity column. The column was
washed with 100 mM Tris, 100 mM NaCl, 2 mM TCEP, 10 μM FeSO4,
20 mM imidazole and the immobilized enzyme eluted with 100 mM
Tris, 100 mM NaCl, 2 mM TCEP, 10 μM FeSO4, 10 μg/ml catalase,
200 mM imidazole. After concentration of the eluant, protein concentration was determined with a Nanodrop spectrophotometer. Protein purity was conﬁrmed by SDS-PAGE. Puriﬁed protein was frozen
dropwise and stored in liquid N2.

4.6. 5-LOX HPLC product analysis of HEK cells
HEK293 cells expressing WT- or TKM-5-LOX with or without FLAP
were collected and resuspended at 1 × 106 cells/ml PBS plus 0.1%
glucose. Each sample was incubated with or without 2.5 μM Ca2+-ionophore A23187 for 5 min at 37 °C then incubated for 10 min with 3 μM
AA (Cayman). Modest substitutions have been shown to eﬀect the kinetics of 5-LOX translocation to the nuclear membrane [11] and preincubation with ionophore was necessary to control for any diﬀerences
in membrane traﬃcking that might result from the substitution of the
KKK motif. Incubations were stopped with the addition of 1 ml (1 volume) of methanol. Prior to solid phase extraction with C18 cartridges
(UCT CLEAN-UP C18 CEC1811Z), 0.5 ml PBS, 30 μl of 1 M HCl, and
10 μl of 50 ng/μl prostaglandin B1 (Cayman, PGB1) were added. The
products were eluted with methanol. The methanol was evaporated oﬀ
under N2 gas and the residue was resuspended in 60% acetonitrile,
0.1% formic acid, the HPLC mobile phase. Samples were treated with
triphenylphosphine as a reducing agent prior to HPLC analysis. Isocratic reverse-phase HPLC was performed with a Supelco Discovery

4.3. TKM-5-LOX puriﬁcation
Bacterial cell cultures prepared as above were lysed by French press.
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rabbit AlexaFluor488 ± donkey anti-goat AlexaFluor647 in a 0.1%
Tween-20 PBS solution for 20 min. After another wash cycle, the cells
were incubated with 2 μg/μl DAPI solution for 3 min followed by another wash cycle. Invitrogen Prolong Gold antifade reagent and a
coverslip were then added to the slide. The slide was imaged with a
Leica DM6B upright microscope using DAPI, GFP (5-LOX), and Cy5
(FLAP) ﬁlters.

HSC18 column monitored at 235 and 270 nm. Peaks for 5-HETE
(235 nm) and PGB1 (270 nm) were integrated. The peaks corresponding
to LTA4-derived breakdown products such as trans-LTB4 or the 5,6 diHETE were identiﬁed by their characteristic UV ﬁne structure, integrated, summed and reported as LT. Product yields were calculated
relative to the peak area of the internal standard PGB1. Activity analysis
for HEK cells expressing TKM-5-LOX and FLAP with only endogenous
AA pools was performed in the same fashion as above (but without
added AA) and 5 incubations were pooled for solid phase extraction of
products (Fig. 8). Statistical analysis was performed in GraphPad Prism
v.7 (GraphPad Software, La Jolla, CA).

4.9. HEK cell protein time-course in the absence of protein synthesis
HEK cells expressing WT- or TKM-5-LOX with or without FLAP were
collected and resuspended at 1 × 106 cells/ml in PBS plus 0.1% glucose. The cells were incubated with or without 2.5 μM Ca2+-ionophore
A23187 for 5 min and then treated with 200 μM cycloheximide at 37 °C
and analyzed at eight time points (0, 60, 90, 120, 150, 180, 210, and
240 min). An extra 200 μM cycloheximide was added after 120 min to
ensure continuous inhibition of protein synthesis. At each time point
2 × 106 cells were treated with lysis buﬀer (50 mM Tris pH 8.0,
150 mM NaCl, 1 mM EDTA, 2% Triton X-100, 1 μM peptstatin, leupeptin and PMSF). Sample protein concentrations were determined
with a BCA assay and equal amounts of protein were loaded onto 10%
SDS-PAGE gels. The samples were then analyzed by Western blot using
rabbit anti-5-LOX “Tail” and goat anti-GAPDH primary antibodies and
donkey anti-rabbit AlexaFluor488 and donkey anti-goat AlexaFluor647
secondary antibodies. Western blots were imaged with a Typhoon 9410
imager using channels 526 SP and 670 30 BP. For quantitative analysis
of western bands we used ImageJ software.

4.7. 5-LOX product analysis of HEK cells analyzed by UPLC-MS-MS
HEK-WT-5-LOX + FLAP
and HEK-TKM-5-LOX + FLAP
cells
(1 × 106/ml) were incubated in PBS containing 1 mM CaCl2. Cells were
stimulated with 2.5 μM A23187 plus 3 μM AA at 37 °C and sampled at 0,
30, 60, 120, 180, 360 and 600 s. Ice-cold methanol (2 ml) was added to
the samples to stop the reaction along with 10 μl of deuterium-labelled
internal standards (200 nM d8-5S-HETE, d4-LTB4) to facilitate quantiﬁcation and sample recovery. Sample preparation was conducted by
adapting published criteria [38,39]. Samples were kept at −20 °C for
60 min to allow protein precipitation. After centrifugation (1200 ×g,
4 °C, 10 min) 8 ml acidiﬁed H2O was added (ﬁnal pH = 3.5) and the
sample was subjected to solid phase extraction. Solid phase cartridges
(Sep-Pak® Vac 6 cc 500 mg/6 ml C18; Waters, Milford, MA) were
equilibrated with 6 ml methanol and 2 ml H2O before samples were
loaded onto columns. After washing with 6 ml H2O and additional 6 ml
hexane, lipid mediators were eluted with 6 ml methyl formate. Finally,
the samples were brought to dryness using an evaporation system
(TurboVap LV, Biotage, Uppsala, Sweden) and resuspended in 100 μl
methanol-water (50/50, v/v) for UPLC-MS-MS automated injections.
Lipid mediator proﬁling was analyzed with an Acquity™ UPLC system
(Waters, Milford, MA, USA) and a QTRAP 5500 Mass Spectrometer
(ABSciex, Darmstadt, Germany) equipped with a Turbo V™ Source and
electrospray ionization (ESI). Lipid mediators were eluted using an
ACQUITY UPLC® BEH C18 column (1.7 μm, 2.1 × 100 mm; Waters,
Eschborn, Germany) at μphase consisting of methanol-water-acetic acid
of 42:58:0.01 (v/v/v) that was ramped to 86:14:0.01 (v/v/v) over
12.5 min and then to 98:2:0.01 (v/v/v) for 3 min [40]. The QTrap 5500
was operated in negative ionization mode using scheduled multiple
reaction monitoring (MRM) coupled with information-dependent acquisition. The scheduled MRM window was 60 s, optimized lipid
mediator parameters were adopted (CE, EP, DP, CXP), and the curtain
gas pressure was set to 35 psi. The retention time and at least six diagnostic ions for each lipid mediator were conﬁrmed by means of an
external standard (Cayman Chemicals/Biomol, Hamburg Germany).
Quantiﬁcation was achieved by calibration curves for each of the lipid
mediators analyzed. Linear calibration curves were obtained that gave
r2 values of 0.998 or higher (for fatty acids 0.95 or higher).

4.10. qPCR HEK 5-LOX mRNA quantiﬁcation
4.10.1. RNA isolation
Samples of 1 × 107 cells were collected for each of the four cell
lines, i.e., WT- or TKM-5-LOX with and without FLAP. After spinning
down cells and removing the media, the cells were resuspended in
Trizol Reagent and incubated for 5 min at room temperature. Then, a
50/50 mixture of chloroform and isoamyl alcohol was mixed with the
samples and allowed to incubate for 3 min at room temperature. After
centrifugation, the upper aqueous phase of the samples was transferred
to a fresh tube. Isopropanol was mixed with aqueous phase and incubated for 10 min at room temperature. The samples were again
centrifuged and the RNA pellet was washed twice with 75% ethanol and
then let to air dry. The RNA pellets were then dissolved in diethylpyrocarbonate (DEPC) water before undergoing DNase treatment where
the samples were incubated with DNase I at 37 °C for 30 min then with
the addition of 10 mM EDTA incubated at 70 °C for 10 min. Next, the
samples were incubated with 300 mM sodium acetate and 2.5 volumes
of ethanol at −80 °C for 15 min before being centrifugation at 4 °C for
10 min. The RNA pellets were dissolved in DEPC water and concentration readings were taken by Nanodrop.
4.10.2. cDNA synthesis and gel analysis
The isolated RNA (10 μg) served as a template for cDNA synthesis
using the Goscript reverse transcriptase kit (Promega). Forward and
reverse oligos for 5-LOXs and the GAPDH control were made by
Integrated DNA Technologies (IDT) (Fig. S4). Samples were then
treated with RNaseH before undergoing PCR. The PCR samples were
run on an Agarose gel and analyzed visually. For quantitative analysis
we used ImageJ software.

4.8. Immunoﬂuorescence imaging of 5-LOX and FLAP in HEK293 cells
HEK293 cells expressing WT- or TKM-5-LOX with or without FLAP
were seeded out at 200 cells/ml in each well of an Ibdi 12-well slide.
After 24–48 h at 37 °C 5% CO2, 2.5 μM Ca2+-ionophore A23187 was
added to stimulate the cells, which were then incubated for 5 min at
37 °C 5% CO2. The cells were ﬁxed with 4% paraformaldye then washed
3 times with PBS. The cells were then incubated with a 50 mM NH4Cl
solution, followed by a wash cycle and subsequently blocked for an
hour with 10% donkey serum, 0.1% Tween-20 in PBS. The samples
were then incubated overnight at 4 °C with a primary antibody solution
consisting of either rabbit anti-5-LOX “Body” ± goat anti-FLAP or
rabbit anti-5-LOX “Tail” ± goat anti-FLAP in 0.1% Tween-20 PBS solution. After a wash cycle with 0.1% Tween-20 PBS the cells were incubated with a secondary antibody solution consisting of donkey anti-
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